Reading SHPH? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track SHPH free→Reading SHPH? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track SHPH free→QuarterlyIQ Insights · SHPH
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
of Form 8-K, the information regarding the Reverse Stock Split (as defined below) contained in
Material Modification to Rights of Security Holders. To the extent required by
Completion of Acquisition or Disposition of Assets. The disclosure required by this Item in connection with the Closing and included in
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Co-Chief Executive Officer On May 4, 2026, in connection with the consummation of the Merger and pursuant to the Merger Agreement, the Board of Directors of Shuttle approved the appointment of Ryan Trasolini, Chief Executive Officer of the Company, as Co-Chief Executive Officer of the Acquiror, effective at the Effective Time. No for…
Unregistered Sales of Equity Securities. The disclosure set forth above in
Entry Into A Material Definitive Agreement. Merger Agreement General Description of the Merger Agreement On May 6, 2026 (the “ Closing Date ”), Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (“ Shuttle ” or “ Acquiror ”), completed its previously announced merger pursuant to an Agreement and Plan of Merger (the “ Merger Agreement ”), entered into on April 30, 2026 by and among the Acquiror, Shuttle Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Shutt…
by reference. The issuance of the Merger Consideration and the offer, sale and issuance of the Securities have not been registered under the Securities Act of 1933, as amended (the “ Securities Act ”), in reliance upon the exemption from registration provided by Section 4(a)(2) of the Securities Act.
Entry Into A Material Definitive Agreement. Merger Agreement General Description of the Merger Agreement On April 30, 2026, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (“ Shuttle ” or “ Acquiror ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Shuttle Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Shuttle (“ Merger Sub ”) and United Dogecoin Inc., a Delaware corporation (the “ Company ”). The transactions contemplat…
Entry into a Material Definitive Agreement. On March 5, 2026, Shuttle Pharmaceuticals Holdings, Inc. (the “Company”) priced its recently announced public offering (the “Offering”) of 2,238,800 shares of the Company’s common stock par value $0.00001 per share (the “Common Stock”), and pre-funded warrants to purchase up to 4,761,200 shares of Common Stock (the “Pre-Funded Warrants”) for aggregate gross proceeds of approximately $3.5 million, before deducting placement agent fees and other offer…
Results of Operations and Financial Condition. On February 11, 2026, Shuttle Pharmaceuticals Holdings, Inc. (the “Company”) filed a registration statement on Form S-1 disclosing certain preliminary estimated unaudited financial results for the full year ended December 31, 2025. The text of the disclosure of those preliminary estimated unaudited financial results is included below. Preliminary Estimated Unaudited Financial Results for the Year Ended December 31, 2025 Set forth below are prelim…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As previously disclosed in our Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on March 12, 2025, in connection with Mr. Christoper Cooper’s appointment to the position of interim co-Chief Executive Officer, on March 11, 2025, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), entered i…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Appointment of Yuying Liang On January 6, 2025, the Board of Directors (the “Board”) of Shuttle Pharmaceuticals Holdings, Inc. (the “Company”) appointed Ms. Yuying Liang, CPA as Chief Financial Officer of the Company. In connection with this appointment, Mr. Chris Cooper will no longer serve as the Company’s Chief Financial Officer (Principal Financ…
Entry into a Material Definitive Agreement. On December 23, 2025 (the “ Effective Date ”), Shuttle Pharmaceuticals Holdings, Inc. (the “ Company ”) entered into a First Amendment (the “ Amendment ”) to Asset Purchase Agreement (the “ Agreement ”) with 1563868 B.C. Ltd., a Canadian limited corporation and the Company’s wholly owned subsidiary (“ Purchaser ”), 1542770 BC Ltd., a Canadian limited corporation (“ Seller ”), and ZhiTian (Andy) Zhang, an individual residing in Vancouver, Canada (“ S…
Unregistered Sales of Equity Securities. The information set forth under in
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On November 21, 2025, Timothy Lorber resigned as Chief Financial Officer of Shuttle Pharmaceuticals Holdings, Inc. (the “Company”), effective immediately. In connection with Mr. Lorber’s resignation, Mr. Lorber and the Company entered into a Separation Agreement and Mutual Release (the “Agreement”). Pursuant to the Agreement, Mr. Lorber will continu…
Entry into a Material Definitive Agreement. On November 20, 2025 (the “ Closing Date ”), Shuttle Pharmaceuticals Holdings, Inc. (the “Company”) entered into an Asset Purchase Agreement (the “ Agreement ”) with 1563868 B.C. Ltd., a Canadian limited corporation and the Company’s wholly owned subsidiary (“ Purchaser ”), 1542770 BC Ltd., a Canadian limited corporation (“ Seller ”) and Zhitian (Andy) Zhang, an individual residing in Vancouver, Canada (“ Seller Guarantor ”). Pursuant to the terms a…
Completion of Acquisition or Disposition of Assets. The disclosure set forth under
Unregistered Sales of Equity Securities. The information set forth under in
Termination of a Material Definitive Agreement. The information set forth above under
Entry into a Material Definitive Agreement. As previously disclosed by the Company in its Current Report on Form 8-K, filed with the U.S. Securities and Exchange Commission (the “SEC”) on October 21, 2025, on October 15, 2025, Shuttle Pharmaceuticals Holdings, Inc. (the “Company”) received a letter from Theradex Systems, Inc. (“Theradex”), providing written notice of termination of the master agreement, dated November 1, 2018 (the “Master Agreement”), between Shuttle Pharmaceuticals, Inc. (th…
contains “forward-looking” statements and estimates, including anticipated winddown costs. These statements are subject to a number of risks and uncertainties that could cause actual results to differ materially, including whether the Company will successfully winddown the Clinical Trials and other risks detailed in the “Risk Factors” section of the Company’s most recent periodic report filed with the SEC. These statements represent the Company’s estimates and assumptions only as of the date…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. Shuttle Pharmaceuticals Holdings, Inc. (the “Company”) reported stockholders’ equity of $1,394,161 in its Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2025, and, as a result, was not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on the Nasdaq Capital Market (“Nasdaq”) to maintain a minimum of $2,500,000 in stockholders’ equity fo…
Entry into a Material Definitive Agreement. Securities Purchase Agreement On November 3, 2025, Shuttle Pharmaceuticals Holdings, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with the purchaser named therein (the “Purchaser”), pursuant to which the Company agreed to issue and sell to the Purchaser in a private placement transaction (the “Offering”) a pre-funded warrant (the “Pre-Funded Warrant”) to purchase up to 625,156 shares of common stock of…
Unregistered Sales of Equity Securities. The information under
Termination of a Material Definitive Agreement. On October 15, 2025, the Company received a letter from Theradex Systems, Inc. (“Theradex”), providing written notice of termination of the master agreement, dated November 1, 2018 (the “Master Agreement”), between Shuttle Pharmaceuticals, Inc. (the Company’s wholly-owned subsidiary) (“Shuttle”) and Theradex, and all work orders thereunder, and demanding immediate payment of all outstanding amounts owed thereunder in the aggregate amount of $1.0…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.